Η εταιρεία μας συμμετέχει στο έργο EDIT της πρόσκλησης Horizon 2020 Fet Open: "Novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma".
EDIT Project will start in 1st October and includes a multi and transdisciplinary consortium capable to develop non-invasive and non-ionizing novel technology and preclinical validation for early prognosis of BCa and therapeutic nanomedicine against bladder Cis. Participating partners are from Greece (Lime), Italy, UK, Israel and Netherlands.
Unmet clinical needs in the management of bladder cancer (BCa) are the prevention of tumor onset, relapse and progression, and therapy of the aggressive carcinoma in situ (Cis), requiring weekly treatments and endless follow-up, with a consequent poor quality of life and the highest cost per patient among all cancers. Therefore, public health programs crave for early BCa detection protocols, to improve performance in the management of this devastating disease. Here we propose an advanced transformative technology termed EDIT combining a novel high-resolution ultrasound elastography and photoacoustic imaging on the bladder instilled with targeted plasmonic gold sensors.
EDIT approach exploits the structural and mechanical properties of the bladder extracellular matrix (ECM) as a unique biomarker of the early onset/progression/relapse of carcinoma, through engineered novel gold nanorods (GNRs) used as intravesical photoacoustic antennas targeted at the ECM, generating an ad hoc visualization platform. GNRs will be further utilized as heat-releasing effectors at nanoscale for targeted cancer photo-thermal therapy. EDIT is designed to detect pre- neoplastic area and eradication of local areas at few cells resolution with high sensitivity and specificity